Compare Ascendis Pharma A/S (ASND) vs D R Horton Inc (DHI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs D R Horton Inc — how do they compare? Ascendis Pharma A/S trades at $255.06 (market cap $16.67B), while D R Horton Inc trades at $146.14 (market cap $42.18B). The key difference: D R Horton Inc is far larger — about 2.5× Ascendis Pharma A/S's market cap, and D R Horton Inc pays a 1.19% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | DHI | |
|---|---|---|
Market Cap | $16.67B | $42.18B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $184.04 |
52-Week Low | $189.74 | $132.53 |
Enterprise Value | $17.04B | $47.28B |
Dividend Yield | — | 1.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.17, down slightly by 0.18% on the day, while maintaining strong analyst support with 92% buy ratings and a $309.75 consensus price target. The company shows impressive revenue growth from $51M in 2022 to $720M in 2025, with profitability improving as net loss narrows to -$228M. Recent technical indicators show a bullish trend with the stock trading near resistance at $255-257, while fundamental metrics reveal high valuation ratios (P/E 29.05, P/S 15.68) offset by exceptional gross margins of 89.04%.
ASND presents a compelling growth story with multiple product launches in rare endocrine diseases driving revenue expansion, though investors face risks from negative shareholder equity and high debt levels. The company's transition to positive operating cash flow ($54M in 2025) and inclusion in Russell indexes signal maturation, but execution risks remain as the stock trades at premium valuations requiring continued strong performance to justify current levels.
D.R. Horton (DHI) trades at $146.44, down slightly by 0.15% today, with a bullish technical signal from moving averages. The company reported Q3 2026 EPS of $3.20, beating estimates, but lowered full-year sales guidance due to soft demand. Valuation metrics appear reasonable with a P/E of 14.37 and P/S of 1.31, while profitability margins have compressed over recent years.
The outlook is mixed: strong cash flow and execution support the stock, but elevated mortgage rates and weak homebuying trends pose headwinds. Analyst consensus is a Buy with a $153 price target, indicating modest upside potential, though risks from housing market volatility persist.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About D R Horton Inc
D.R. Horton is a leading homebuilder in the United States with operations in 98 markets across 31 states. D.R. Horton mainly builds single-family detached homes (over 90% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's headquarters are in Arlington, Texas, and it manages six regional segments across the United States.
Read more on DHI →
